FIELD: medicine; pharmaceutics.
SUBSTANCE: invention relates to health care. Disclosed is the use of a hexapeptide of formula (I): H-Tyr-D-Ala-Gly-Phe-Leu-Arg-OH (I) or a pharmaceutically acceptable salt thereof for reducing levels of extracellular HMGB1 in a mammal in need thereof.
EFFECT: invention provides a decrease in the level of extracellular HMGB1, an inflammation mediator that aggravates the clinical course of the inflammatory disease.
3 cl, 3 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HEPTAPEPTIDE AMIDES FOR THE TREATMENT OF HMGB1-DEPENDENT DISEASES | 2021 |
|
RU2760133C1 |
| METHOD FOR TREATMENT OF LUNG DISEASES BY INHALATION ADMINISTRATION OF MESENCHYMAL STROMAL CELLS AND HEXAPEPTIDE | 2022 |
|
RU2770364C1 |
| BIOMEDICAL CELL PRODUCT BASED ON MAMMALIAN MESENCHYMAL STROMAL CELLS AND HEXAPEPTIDE | 2022 |
|
RU2781968C1 |
| INHALED HEXAPEPTIDE FOR TREATING RESPIRATORY DISEASES ASSOCIATED WITH INTERLEUKIN-6 | 2020 |
|
RU2737799C1 |
| GROWTH HORMONE RECEPTOR BLOCKERS FOR DISEASE PREVENTION AND TREATMENT | 2016 |
|
RU2726254C2 |
| PAIN TREATMENT | 2009 |
|
RU2712166C2 |
| IL-10/FC FUSION PROTEINS SUITABLE AS IMMUNOTHERAPY ENHANCERS | 2020 |
|
RU2825306C1 |
| CHIMERIC ANTIGEN RECEPTORS M971 | 2018 |
|
RU2770411C1 |
| SUSTAINED RELEASE PHARMACEUTICAL COMPOSITION IN THE FORM OF A SUPPOSITORY CONTAINING HEXAPEPTIDE | 2020 |
|
RU2737800C1 |
| USING DALARGIN FOR PRODUCING AGENTS FOR TREATING COVID-19 CORONAVIRUS INFECTION | 2020 |
|
RU2728939C1 |
